Delve Bio Announces Clinical Data on the Use of Metagenomic Next-Generation Sequencing (mNGS) to Identify Pathogens Causing Central Nervous System Infections

Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, in collaboration with the University of California, San Francisco (UCSF), today announced data from a study highlighting the utility and diagnostic yield of mNGS testing in cases of infectious meningitis, encephalitis, and/or myelitis among both adults and children at the American Society of Microbiology Microbe conference in Atlanta.

Congratulations to Michael Wilson, Joe DeRisi, and Charles Chiu, the UCSF founders of Delve Bio.